United States Patent 12,171,883 (Budesonide Extended-Release, Enteric-Coated Capsules) Claim Scope and Competitive Patent Landscape
What is US Drug Patent 12,171,883 and what does it claim?
Executive summary: US 12,171,883 is directed to a budesonide capsule formulation built from multiple budesonide cores encapsulated in a capsule, where each core is coated with an extended-release polymeric blend of ethylcellulose and hydroxypropylmethyl cellulose (HPMC) in specified weight-fraction ranges, and where the capsule is further covered by an enteric coating specified in mg per capsule. The claims are defined by a USP<711> Apparatus 2 (paddle) release profile that requires strong pH-dependent protection in early stages and substantial release later, specifically targeting pH 1.2 and intestinal pH 6.5/6.8 dissolution media.
Claim 1: core polymer blend + enteric coating + USP<711> release profile (the main independent claim)
Claim 1 requires all of the following elements:
A. Dosage form structure
- Plurality of cores comprising budesonide encapsulated within a capsule (claim language is unusual because “cores” are said to be “encapsulated within a capsule,” but functionally this reads as multi-part cores inside a capsule shell that also carries an enteric coat).
- Each core is coated with an extended-release polymeric blend.
B. Extended-release polymeric blend composition
- The extended-release pharmaceutically-acceptable polymeric blend must contain:
- Ethylcellulose: from ~47 wt.% to ~56 wt.% of the polymeric blend
- Hydroxypropylmethyl cellulose (HPMC): from ~32 wt.% to ~22 wt.% of the polymeric blend
- (The two ranges as written overlap and imply a constrained blend where the blend components sum to the blend total; the claim frames both ranges simultaneously.)
C. Amount of extended-release polymeric blend
- Polymer blend amount is 5 wt.% to ~18 wt.% of the total coated core weight.
D. Enteric coating amount
- Capsule enteric coating present at ~34 mg to ~46 mg per capsule.
E. In vitro dissolution release criteria (USP<711>, Apparatus 2, 100 rpm)
The formulation must meet all three release constraints:
- Acid stage:
- In aqueous pH ~1.2 within 120 minutes
- No more than ~10% budesonide released.
- Early intestinal stage:
- In “pharmaceutically-relevant dissolution medium” within 30 minutes, where:
- Level 1 Fasted State Simulated Intestinal Fluid (FaSSIF) at pH ~6.5, or
- phosphate buffer at pH ~6.8
- No more than ~10% budesonide released in that 30-minute window.
- Later intestinal stage:
- In the pharmaceutically-relevant dissolution medium within 120 minutes
- At least ~70% budesonide released.
Practical meaning: the claim is not simply compositional. It ties polymer composition and coating mass to a specific budesonide release delay in acid and early intestine, followed by bulk release by 120 minutes. That combination is typically where design-around efforts fail, because many “similar” enteric and matrix combinations miss one of the time/pH windows.
Claims 2–7: narrowing capsule size and actives dose
- Claim 2: capsule is size 1.
- Claim 3: capsule comprises about 4 mg budesonide.
- Claim 4: polymer blend amount narrower: ~6 wt.% to ~13 wt.% of coated core weight.
- Claim 5: polymer blend amount set to 9.1 wt.% (±2%) of coated core weight.
- Claim 6: enteric coating amount narrower: ~34 mg to ~42 mg per capsule.
- Claim 7: capsule is size 1 (again).
Claims 8–14: second embodiment with specific blend ratios (ethylcellulose ~51.8% and HPMC ~27.3%)
Claim 8 is an independent claim mirroring claim 1, but with a different specification for polymer blend ratios:
- Ethylcellulose: ~51.8 wt.% of polymeric blend
- HPMC: ~27.3 wt.% of polymeric blend
- All other conditions replicate: polymer amount 5–18 wt.% of coated core weight, enteric coating 34–46 mg per capsule, and the same USP<711> release profile constraints.
Dependent/narrowing claims:
- Claim 9: capsule size 1
- Claim 10: capsule has about 4 mg budesonide
- Claim 11: polymer blend amount 6–13 wt.%
- Claim 12: polymer blend amount 9.1 wt.% (±2%)
- Claim 13: enteric coating 34–42 mg per capsule
- Claim 14: capsule size 1
Bottom line on claim scope:
The patent simultaneously covers:
- A composition-of-matter-like “formula space” (polymer blend composition and mass)
- A process-adjacent functional profile through USP<711> dissolution tests
- A packaging and shell parameter space (enteric coating mg per capsule; size 1; ~4 mg dose)
Which product attributes matter most for infringement risk under this claim?
Executive snippet: For infringement, you typically need to match the polymer blend composition ranges, the polymer fraction of coated cores, the enteric coating mg per capsule, and the USP<711> dissolution release profile windows.
Key infringement “lock points”
- Ethylcellulose/HPMC composition range
- Claim 1 requires 47–56% ethylcellulose within the polymeric blend, with HPMC 32–22%.
- Claim 8 uses specific ratios (51.8% ethylcellulose; 27.3% HPMC).
- Polymer blend amount vs coated core weight
- Must land in 5–18 wt.% (broad independent claim constraint).
- Dependent claims lock 6–13 wt.% and even ~9.1 wt.% ±2%.
- Enteric coating mg per capsule
- 34–46 mg (independent claims).
- 34–42 mg (dependent claims).
- Dissolution performance with explicit time and pH
- ≤10% release at pH 1.2 by 120 minutes
- ≤10% release at pH 6.5 (FaSSIF) or pH 6.8 buffer by 30 minutes
- ≥70% release by 120 minutes in those intestinal media
Design-around pressure: A competitor can alter polymer chemistry, polymer blending ratio, or coat mass, but the dissolution constraints make “close substitutes” high-risk unless they replicate the time-pH release curve.
What patents does US 12,171,883 likely sit among in the budesonide capsule landscape?
Executive summary: Given the claim architecture, US 12,171,883 fits into the intersection of three common budesonide IP clusters:
- Controlled-release and enteric budesonide oral dosage forms (pH-triggered delivery)
- Specific polymer blends and coat weights (ethylcellulose/HPMC in defined proportions and amounts)
- Method-of-formulation functional dissolution profiles (USP<711>-style criteria)
However, without the patent record (title, assignee, family, and cited documents), the precise constellation of related US patents cannot be enumerated accurately from the claim text alone.
How strong is the patent estate implied by the claims?
Executive snippet: Strength is driven by the claim’s combination of (i) constrained polymer ratios and coat masses and (ii) explicit dissolution performance metrics in two pH environments with defined time windows.
Strength drivers
- Functional performance limitations increase practical validity leverage because they tie the scope to measurable outcomes.
- The polymer composition and coating amounts narrow “almost equivalent” formulations.
- The USP<711> Apparatus 2 at a defined rotation speed (100 rpm) reduces ambiguity and can constrain expert disputes about test setup.
Weakness vectors (where challengers typically attack)
- If prior art already used ethylcellulose + HPMC blends for budesonide with comparable coat weights and similar dissolution behavior, novelty and/or obviousness risk rises.
- If a competitor argues that the dissolution profile depends on unclaimed formulation variables (e.g., core size distribution, processing parameters, budesonide particle size, or exact enteric polymer grade), infringement may become a battle over test conditions and formulation equivalence.
When does US 12,171,883 lose exclusivity?
Executive summary: None of the term-ending dates, patent term adjustments, or terminal disclaimers can be calculated from claim text alone.
What generics or biosimilars risk profile does this create?
Executive summary: This is an oral small-molecule budesonide formulation patent, not a biologic. The risk profile is for ANDA-style generic challenge (and possibly 505(b)(2) competitors), not biosimilar substitution.
Generic entry risk is highest when a challenger can copy all three constraints
- The polymer blend ratio within claim-defined windows
- The enteric coat mg per capsule
- The dissolution release profile in pH 1.2 and intestinal media at the specified time points
What tends to happen in litigation for this type of claim
- Claim construction will focus on:
- whether “no more than about 10%” is treated with a strict numerical tolerance in practice
- whether the “pharmaceutically relevant dissolution medium” is satisfied if a challenger uses alternate intestinal simulated fluids within the same pH but different compositions
What formulation design-arounds are most plausible versus most likely to fail?
Executive summary: The patent’s tight coupling of composition to dissolution profile makes design-around more about re-engineering release kinetics than about swapping excipients.
More plausible changes (still high validation burden)
- Shift polymer blend composition just outside the defined ethylcellulose and/or HPMC ranges, then re-optimize coating mass and core loading.
- Adjust enteric coat mg per capsule to change lag time in pH 6.5/6.8 while maintaining ≤10% release at 30 minutes and ≥70% by 120 minutes.
Higher failure likelihood
- Minor adjustments that preserve the same release curve because the claim is functional.
- Changing test parameters (apparatus speed, medium composition, sampling schedule) does not avoid infringement if the product meets the claimed profile under USP<711> and the medium definitions specified.
How does this patent compare with other budesonide oral controlled-release approaches?
Executive summary: The claim specifically matches an enteric-delayed, extended-release capsule design. Other budesonide products typically use different release mechanisms (e.g., alternative core matrices, different coating polymers, or differing multi-part structures). The closest comparisons in practice are other enteric + extended-release budesonide capsule platforms that target early intestinal protection and late release.
Without a verified citation map to specific competitors and their formulations, a precise side-by-side comparison cannot be stated.
Key Takeaways
- US 12,171,883 claims a multi-core budesonide capsule with enteric coating and per-core extended-release coating.
- Scope is defined by both composition (ethylcellulose/HPMC ratios and polymer coat weight fraction) and performance (USP<711> Apparatus 2 at 100 rpm with quantified release limits at pH 1.2 and pH 6.5/6.8 at 30 and 120 minutes).
- The most infringement-relevant “lock points” are the polymer blend ratio windows, 5–18 wt.% (and narrower dependent ranges), 34–46 mg enteric coat per capsule, and the ≤10%/≤10%/≥70% dissolution profile.
- Term and exact landscape ranking require the patent’s bibliographic record, family data, and cited prior art, which are not provided in the prompt.
FAQs
-
Does US 12,171,883 require exact USP<711> Apparatus 2 conditions to be met?
Yes. The claim specifies USP<711> Apparatus 2 (paddle) at 100 rpm, tying infringement to that test configuration.
-
Is the dissolution medium pH 6.5 or pH 6.8 interchangeable?
The claim accepts either Level 1 FaSSIF at pH ~6.5 or phosphate buffer at pH ~6.8.
-
Can a competitor avoid infringement by using different capsule size or budesonide dose?
Dependent claims include size 1 and ~4 mg, but the independent claim already covers “capsule” without those narrow limits; avoiding dependent claims may not avoid independent-claim coverage.
-
Which parameter is usually hardest to match: polymer ratio, coat weight, or dissolution kinetics?
The claim’s performance requirements make the dissolution kinetics hardest to replicate across formulation variants.
-
Is this patent relevant to 505(b)(2) products as well as ANDAs?
Yes, because it targets the formulation and performance characteristics that such applications would need to match if relying on the claimed formulation’s therapeutic equivalence.
References (APA)
- United States Patent No. 12,171,883 (claims as provided).
